logo
#

Latest news with #INSP

Inspire Medical (INSP) Takes 32% Nosedive on Dismal Earnings, Outlook
Inspire Medical (INSP) Takes 32% Nosedive on Dismal Earnings, Outlook

Yahoo

time2 days ago

  • Business
  • Yahoo

Inspire Medical (INSP) Takes 32% Nosedive on Dismal Earnings, Outlook

We recently published . Inspire Medical Systems, Inc. (NYSE:INSP) is one of the worst-performing stocks on Tuesday. Inspire Medical nosedived by 32.35 percent on Tuesday to end at $87.91 apiece as investors unloaded portfolios following a disappointing earnings performance in the second quarter of the year, coupled with a lower growth outlook for the full year. This followed the company's swing to a $3.59 million net loss in the second quarter of the year, reversing a $9.8 million net income in the same period last year. Revenues, however, jumped by 10.7 percent to $217 million from $195.88 million in the same comparable period. In the first half, Inspire Medical Systems, Inc. (NYSE:INSP) said it widened its net loss by 183 percent to $600 million from $212 million, while revenues grew by 16 percent to $418 million from $360 million. Commenting on the company's performance, Inspire Medical Systems, Inc. (NYSE:INSP) Chairman and CEO Tim Herbert believed that operational headwinds were just temporary and that actions are underway to address them. Copyright: lenetstan / 123RF Stock Photo For full-year 2025, the company expects revenues to now settle between $900 million and $910 million, lower than the $940 million to $955 million expected previously. While we acknowledge the potential of INSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Inspire Medical Systems Stock (INSP) Dives After Reporting a Q2 Beat & Guidance Cut
Inspire Medical Systems Stock (INSP) Dives After Reporting a Q2 Beat & Guidance Cut

Business Insider

time3 days ago

  • Business
  • Business Insider

Inspire Medical Systems Stock (INSP) Dives After Reporting a Q2 Beat & Guidance Cut

Inspire Medical Systems (INSP) stock plummeted on Tuesday following the release of the medical technology company's Q2 2025 earnings report. This started with adjusted earnings per share of 45 cents, compared to Wall Street's estimate of 20 cents. The company's adjusted EPS also increased 40.63% year-over-year from 32 cents. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Inspire Medical Systems reported revenue of $217.1 million in Q2, which surpassed analysts' estimate of $214.49 million. It was also up 11% from the $195.88 million reported in the second quarter of 2024. This was fueled by the launch of its Inspire V system in the U.S. However, investors' hopes were hurt when Inspire Medical Systems Chairman and CEO Tim Herbert noted that 'the U.S. commercial launch is progressing slower than expected, and the timeline to complete the full transition to Inspire V has been pushed forward, which will impact financial results for the year.' Inspire Medical Systems Guidance Inspire Medical Systems lowered its 2025 guidance in its latest earnings report. It now expects revenue for the year to range from $900 million to $910 million, compared to its previous estimate of $940 to $955 million. This would also see it miss Wall Street's 2025 revenue estimate of $914.74 million. Inspire Medical Systems stock was down 30.48% in pre-market trading on Tuesday, following a 3.05% rally yesterday. The shares have also decreased 29.9% year-to-date and 11.6% over the past 12 months. The guidance cut announced by Inspire Medical Systems has already resulted in several lowered price targets, including UBS analyst Danielle Antalffy cutting her price target for INSP shares to $230 from $270. Is Inspire Medical Systems Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Inspire Medical Systems is Strong Buy, based on 10 Buy and three Hold ratings over the past 12 months. With that comes an average INSP stock price target of $210.09, representing a potential 61.67% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today's earnings report.

INSP Stock Plunges Despite Q2 Earnings Beat, Gross Margin Contracts
INSP Stock Plunges Despite Q2 Earnings Beat, Gross Margin Contracts

Yahoo

time3 days ago

  • Business
  • Yahoo

INSP Stock Plunges Despite Q2 Earnings Beat, Gross Margin Contracts

Inspire Medical Systems, Inc. INSP delivered an earnings per share (EPS) of 45 cents in second-quarter 2025, up 40.6% year over year. The figure topped the Zacks Consensus Estimate by 104.6%. INSP's Revenues in Detail Inspire Medical registered revenues of $217.1 million in the second quarter, up 10.8% year over year. The figure beat the Zacks Consensus Estimate by 0.9%. Per management, the overall revenue growth was primarily driven by increased market penetration and increased physician and patient awareness of the Inspire system. However, this was partially offset by ENT surgeon capacity constraints and some U.S. patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications. Shares of this company lost nearly 24.9% in today's pre-market trading. Inspire Medical's Segment Details Inspire Medical's operations consist of two geographic regions — the United States and All other countries. In the quarter under review, U.S. revenues of $207.2 million reflected an increase of 10.3% from the year-ago quarter on a reported basis. As of June 30, 2025, Inspire Medical had 348 U.S. sales territories and 259 field clinical representatives compared with 335 and 230, respectively, as of Dec. 31, 2024. Revenues from All other countries totaled $9.9 million, up 23% year over year on a reported basis. Inspire Medical Systems, Inc. Price, Consensus and EPS Surprise Inspire Medical Systems, Inc. price-consensus-eps-surprise-chart | Inspire Medical Systems, Inc. Quote INSP's Margin Analysis In the second quarter, Inspire Medical's gross profit increased 9.9% year over year to $182.4 million. However, the gross margin contracted 74 basis points (bps) to 84%. Selling, general and administrative expenses jumped 20.8% year over year to $159.5 million. Research and development expenses decreased 9.2% year over year to $26.2 million. Operating expenses of $185.7 million increased 15.4% year over year. Operating loss totaled $3.3 million against the prior-year quarter's operating profit of $5.1 million. Inspire Medical's Financial Position Inspire Medical exited second-quarter 2025 with cash and cash equivalents and short-term investments of $300.9 million compared with $369.2 million at the first-quarter end. Cumulative net cash used in operating activities at the end of second-quarter 2025 was $4 million, against net cash provided by operating activities of $8.8 million a year ago. INSP's Outlook Inspire Medical has lowered its revenue and EPS outlook for 2025. The company now projects revenues in the range of $900 million-$910 million (representing growth of 12-13% from 2024 levels), lowered from the prior outlook of $940 million-$955 million (representing growth of 17-19% from 2024 levels). The Zacks Consensus Estimate is pegged at $949.1 million. The company now expects its EPS for 2025 to be between 40 cents and 50 cents, lowered from the prior outlook of $2.20-$2.30. The Zacks Consensus Estimate is pegged at $2.26. Our Take on Inspire Medical Inspire Medical exited the second quarter of 2025 with better-than-expected results. The robust improvement of the top and bottom lines was impressive. Strength in year-over-year geographical revenues was promising. The increased market penetration and increased physician and patient awareness of the Inspire system during the reported quarter were encouraging. However, the gross margin contracted due to rising product costs. This does not bode well for the stock. Also, management's confirmation about the slower-than-expected progress of the U.S. commercial launch of Inspire V is worrying. Per management, this has resulted in the pushing forward of the timeline to complete the full transition to Inspire V, which will impact financial results for the year. INSP's Zacks Rank and Key Picks Inspire Medical currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank stocks here. GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Romania reports 1,703 new COVID-19 cases, 7 deaths in July
Romania reports 1,703 new COVID-19 cases, 7 deaths in July

The Star

time4 days ago

  • Health
  • The Star

Romania reports 1,703 new COVID-19 cases, 7 deaths in July

BUCHAREST, Aug. 4 (Xinhua) -- Romania recorded 1,703 new cases of COVID-19 in July 2025, marking a 232 percent increase compared to the previous month, according to data released on Monday by the National Institute of Public Health (INSP). Of the total cases, 442 were reinfections, occurring more than 90 days after the initial diagnosis. The INSP also reported seven COVID-19-related deaths in July, involving five men and two women. Four of the individuals were aged 70 to 79, and three were over 80. All had underlying health conditions. Testing activity increased last month, with 860 RT-PCR tests and 14,750 rapid antigen tests performed, up 25.5 percent from June. The overall positivity rate rose to 10.9 percent, an increase of 6.8 percentage points. As of July 31, Romania had recorded 3,586,193 confirmed COVID-19 cases and 69,266 related deaths since the start of the pandemic.

Mihas 2025 to strengthen halal trade
Mihas 2025 to strengthen halal trade

The Star

time5 days ago

  • Business
  • The Star

Mihas 2025 to strengthen halal trade

Representatives engaging in business discussions at the International Sourcing Programme (INSP) during Mihas 2024, showcasing global partnerships and trade opportunities in the halal industry. PARIS: Malaysia is set to welcome global halal industry leaders to the 21st edition of the Malaysia International Halal Showcase (Mihas 2025), taking place from Sept 17 to 20 at the Malaysia International Trade and Exhibition Centre (Mitec) in Kuala Lumpur. Hosted by the Investment, Trade and Industry Ministry (Miti) and organised by the Malaysia External Trade Development Corporation (Matrade), Mihas continues to serve as the world's largest halal trade exhibition — bringing together buyers, sellers and industry leaders from over 90 countries. This year, five French buyers from the modest fashion as well as food and beverage sectors are confirmed to participate in Mihas' flagship International Sourcing Programme (INSP). Their participation reflects the growing global recognition of halal certification as a mark of quality, traceability and ethical assurance for consumers worldwide, regardless of faith. 'Mihas is more than a trade event — it is a global platform for innovation, sustainability and quality,' said Malaysia's ambassador to France Datuk Eldeen Husaini Mohd Hashim. 'Halal is increasingly recognised worldwide as a value-based certification that ensures safety, cleanliness and integrity. 'Mihas is more than a trade event — it is a global platform for innovation, sustainability and quality,' said Eldeen Husaini. 'It is not just for Muslims — it represents a trusted system of quality control, traceability and ethical assurance for all consumers. I am delighted to see significant French participation this year, as Malaysia continues to build bridges across halal economies and open new avenues for global partnerships.' In line with current market trends, Mihas also showcases products that emphasise organic, vegan and sustainable practices, broadening its appeal to the conscious consumer segment worldwide According to the Halal Industry Master Plan (HIMP), demand for halal products is estimated at over US$3 trillion and is projected to reach US$ 5 trillion by 2030. 'Beyond Malaysia, Mihas is a strategic gateway to the wider Asean market of over 680 million people,' said Sebastien Chan Yik Sing, the newly appointed economic counsellor at the Embassy of Malaysia in Paris, succeeding Zuhaila Sedek. 'French buyers can leverage Mihas not only to source quality halal products, but also to connect with the fast-growing Asean market through Malaysia's trusted and well-established halal ecosystem.' As Malaysia assumes the Asean chairmanship in 2025, halal trade has been elevated as one of the Priority Economic Deliverables (PEDs). Mihas 2025 will reflect this emphasis through special Asean and Gulf Cooperation Council (GCC) pavilions — further connecting regional and international halal markets. In 2024, Mihas recorded RM4.3bil in sales and welcomed over 43,000 visitors. The upcoming 21st edition, themed 'Pinnacle of Halal Excellence,' aims to surpass these milestones with a sales target of RM4.5bil, featuring cutting-edge artificial intelligence (AI) tools via the Madani Digital Trade (MDT) platform to enhance real-time sourcing, matchmaking and trade connections. For more information about Mihas and participation opportunities, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store